Biotech | November 26, 2025
Novartis scores FDA nod for game-changing SMA treatment
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
A key highlight will be Brenntag’s qualified amino acids portfolio
The multibillion-dollar Maryland expansion is part of AstraZeneca’s sweeping $50 billion global investment plan
The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks
Both companies will jointly execute development and scale-up of multiple strategic APIs, including late-stage NCE-1 opportunities
Developed in partnership with the Johns Hopkins Applied Physics Laboratory (APL), the module is built around a multi-segment RT-PCR method with integrated indexing
SMDC is a participating authority under Pharmaceutical Inspection Cooperation Scheme (PIC/S)
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
Diversifying its portfolio to include late-phase antiviral agent
Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
